| DATE | RELEASE |
|---|---|
| 2021-08-24 |
NeuroVision Imaging Inc., Announces Additional Funding from the ADDF to Accelerate Development of Novel Blood-Based Lab Test to Predict Dementia Before Clinical Onset "Our best chance at stopping this disease in its tracks is by advancing the most promising research across the globe. Development of a blood test for biomarker detection and monitoring could be a major step in this process,” said Howard Fillit, M.D., Founding Executive Director and Chief Science Officer at the ADDF. |
| 2021-08-23 | Eyes Provide Peek at Alzheimer’s Disease Risk - University of California San Diego School of Medicine Research Report…"these findings are encouraging because they suggest it may be possible to determine the onset, spread and morphology of AD — a preclinical diagnosis — using retinal imaging, rather than more difficult and costly brain scans,” said senior author Robert Rissman, PhD, professor of neurosciences at UC San Diego School of Medicine. |
| 2021-02-01 | NeuroVision Imaging Inc., Announces New Funding from the ADDF to Develop Affordable, Accessible Biomarkers to Diagnose Alzheimer’s and Related Dementias"We recently discovered that beta-amyloid complexes in the blood can reflect amyloid load in the brain, and we developed technology that allows us to measure these protein complexes in the blood. Our work has shown that the determination of these complexes can identify people at the earliest stages of Alzheimer’s,” said Blaine Roberts, PhD, Associate Professor of Biochemistry at Emory University School of Medicine and co-Investigator. |
| 2021-07-08 | Alzheimer’s Therapeutics Research Leader Dr. Roy Twyman Joins NeuroVision Imaging BoardTwyman Served as Senior Vice President at Janssen Pharmaceutical Research & Development, Overseeing Alzheimer’s Disease Therapeutics, and has served on advisory committees and panels of the U.S. Food and Drug Administration and the Institute of Medicine. |
| 2018-05-02 | NeuroVision Announces a $15 Million Series C Financing with a first close of $11.2 Million"It is imperative that innovative companies find solutions to this growing threat [millions of Americans living with Alzheimer’s], and that depends on quality organizations providing the resources to support their work,” said Leonard Potter, chief investment officer and president of Wildcat Capital Management. |
| 2017-08-22 | Clinical Study Shows That Retinal Imaging May Detect Signs Of Alzheimer’s Disease"This is the first study demonstrating the potential to image and quantify retinal findings related to beta-amyloid plaques noninvasively in living patients using a retinal scan with high resolution", said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai Medical Center. |
| 2017-02-27 | NeuroVision Announces Participation in Landmark Alzheimer’s A4 Study Evaluating Its Novel Retinal Imaging Technology"If successful, this technique could one day be used in the clinic to identify at‐risk patients,” said Dr. Michael Rafii, associate professor of neurology at USC and associate professor of neurosciences at UC San Diego. |
| 2016-05-31 | NeuroVision Announces $10 Million Series B Financing Led by Wildcat Capital Management with $5 Million"NeuroVision is putting together an impressive scientific track record and garnering the attention of other organizations dedicated to finding answers to the threat of Alzheimer’s disease, which often is likened to a developing tsunami,” Leonard Potter said. |
| 2016-02-09 | NeuroVision Expands Collaboration with Janssen Research & Development LLC to Advance Alzheimer’s ResearchThe collaboration will enable NeuroVision to further validate its retinal imaging technology and develop its technology for potential early detection and monitoring of amyloid pathology related to Alzheimer’s disease. |
